1. Use of a compound selected from the group consisting of fibroblast growth factor 23 (FGF23), inorganic phosphorus (P), phosphorus and total calcium (P × tCa), osteopontin (OPN) and parathyroid hormone (PTH) as a biomarker for control of inhibition of kinase activity of FGFR.2. The use according to claim 1, wherein the compound is inorganic phosphorus (P). The use according to claim 1, wherein the compound is FGF23.4. The use according to claim 1, 2 or 3 for determining therapeutic efficacy and / or one or more secondary effects of an FGFR inhibitor. The use according to claim 4, wherein the therapeutic efficacy is selected from the group consisting of treating, preventing or delaying the progression of the proliferative disease and / or non-cancerous disorders. The use according to claim 4, where the secondary effect is an ectopic mineralization. The use according to claim 4, wherein the FGFR inhibitor is a macromolecule. The use according to claim 4, wherein the FGFR inhibitor is a low molecular weight molecular compound. The use according to claim 8, wherein the FGFR inhibitor is Compound A (3- (2,6-dichloro-3,5-dimethoxyphenyl) -1- {6- [4- (4-ethylpiperazin-1-yl) phenylamino] pyrimidine -4-yl} -1-methyl-urea) or TKI258.10. The use according to claim 8, wherein the FGFR inhibitor is Compound A 3- (2,6-dichloro-3,5-dimethoxyphenyl) -1- {6- [4- (4-ethylpiperazin-1-yl) phenylamino] pyrimidin- 4-yl} -1-methyl-urea). 11. A method for determining inhibition of fibroblast growth factor (FGFR) receptor kinase activity, comprising the steps of: a administering an FGFR inhibitor to an individual b) taking a sample from said individual c) determining the level of FGF23 or the level of inorganic phosphorus (P) of said sample and d) comparing said ur1. Применение соединения, выбранного из группы, состоящей из фактора роста фибробластов 23 (FGF23), неорганического фосфора (P), произведение фосфора и общего кальция (P×tCa), остеопонтина (OPN) и паратиреоидного гормона (PTH) в
